Getting the balance right: Established and emerging therapies for major depressive disorders

Bojana Perovic, Marija Jovanovic, Branislava Miljkovic, Sandra VezmarDepartment of Pharmacokinetics, Faculty of Pharmacy, University of Belgrade, SerbiaAbstract: Major depressive disorder (MDD) is a common and serious illness of our times, associated with monoamine deficiency in the brain. Moreover,...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Bojana Perovic, Marija Jovanovic, Branislava Miljkovic, et al
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/e98490cda2b04bd28daa0340b820d1c9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:e98490cda2b04bd28daa0340b820d1c9
record_format	dspace
spelling	oai:doaj.org-article:e98490cda2b04bd28daa0340b820d1c92021-12-02T03:48:31ZGetting the balance right: Established and emerging therapies for major depressive disorders1176-63281178-2021https://doaj.org/article/e98490cda2b04bd28daa0340b820d1c92010-07-01T00:00:00Zhttp://www.dovepress.com/getting-the-balance-right-established-and-emerging-therapies-for-major-a4755https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Bojana Perovic, Marija Jovanovic, Branislava Miljkovic, Sandra VezmarDepartment of Pharmacokinetics, Faculty of Pharmacy, University of Belgrade, SerbiaAbstract: Major depressive disorder (MDD) is a common and serious illness of our times, associated with monoamine deficiency in the brain. Moreover, increased levels of cortisol, &shy;possibly caused by stress, may be related to depression. In the treatment of MDD, the use of older antidepressants such as monoamine oxidase inhibitors and tricyclic antidepressants is decreasing rapidly, mainly due to their adverse effect profiles. In contrast, the use of serotonin reuptake inhibitors and newer antidepressants, which have dual modes of action such as inhibition of the serotonin and noradrenaline or dopamine reuptake, is increasing. Novel antidepressants have additive modes of action such as agomelatine, a potent agonist of melatonin receptors. Drugs in development for treatment of MDD include triple reuptake inhibitors, dual-acting serotonin reuptake inhibitors and histamine antagonists, and many more. Newer antidepressants have similar efficacy and in general good tolerability profiles. Nevertheless, compliance with treatment for MDD is poor and may contribute to treatment failure. Despite the broad spectrum of available antidepressants, there are still at least 30% of depressive patients who do not benefit from treatment. Therefore, new approaches in drug development are necessary and, according to current research developments, the future of antidepressant treatment may be promising.Keywords: major depressive disorders, monoamine deficiency, antidepressants, depression Bojana PerovicMarija JovanovicBranislava Miljkovicet alDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2010, Iss Issue 1, Pp 343-364 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Bojana Perovic Marija Jovanovic Branislava Miljkovic et al Getting the balance right: Established and emerging therapies for major depressive disorders
description	Bojana Perovic, Marija Jovanovic, Branislava Miljkovic, Sandra VezmarDepartment of Pharmacokinetics, Faculty of Pharmacy, University of Belgrade, SerbiaAbstract: Major depressive disorder (MDD) is a common and serious illness of our times, associated with monoamine deficiency in the brain. Moreover, increased levels of cortisol, &shy;possibly caused by stress, may be related to depression. In the treatment of MDD, the use of older antidepressants such as monoamine oxidase inhibitors and tricyclic antidepressants is decreasing rapidly, mainly due to their adverse effect profiles. In contrast, the use of serotonin reuptake inhibitors and newer antidepressants, which have dual modes of action such as inhibition of the serotonin and noradrenaline or dopamine reuptake, is increasing. Novel antidepressants have additive modes of action such as agomelatine, a potent agonist of melatonin receptors. Drugs in development for treatment of MDD include triple reuptake inhibitors, dual-acting serotonin reuptake inhibitors and histamine antagonists, and many more. Newer antidepressants have similar efficacy and in general good tolerability profiles. Nevertheless, compliance with treatment for MDD is poor and may contribute to treatment failure. Despite the broad spectrum of available antidepressants, there are still at least 30% of depressive patients who do not benefit from treatment. Therefore, new approaches in drug development are necessary and, according to current research developments, the future of antidepressant treatment may be promising.Keywords: major depressive disorders, monoamine deficiency, antidepressants, depression
format	article
author	Bojana Perovic Marija Jovanovic Branislava Miljkovic et al
author_facet	Bojana Perovic Marija Jovanovic Branislava Miljkovic et al
author_sort	Bojana Perovic
title	Getting the balance right: Established and emerging therapies for major depressive disorders
title_short	Getting the balance right: Established and emerging therapies for major depressive disorders
title_full	Getting the balance right: Established and emerging therapies for major depressive disorders
title_fullStr	Getting the balance right: Established and emerging therapies for major depressive disorders
title_full_unstemmed	Getting the balance right: Established and emerging therapies for major depressive disorders
title_sort	getting the balance right: established and emerging therapies for major depressive disorders
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/e98490cda2b04bd28daa0340b820d1c9
work_keys_str_mv	AT bojanaperovic gettingthebalancerightestablishedandemergingtherapiesformajordepressivedisorders AT marijajovanovic gettingthebalancerightestablishedandemergingtherapiesformajordepressivedisorders AT branislavamiljkovic gettingthebalancerightestablishedandemergingtherapiesformajordepressivedisorders AT etal gettingthebalancerightestablishedandemergingtherapiesformajordepressivedisorders
_version_	1718401619307003904

Getting the balance right: Established and emerging therapies for major depressive disorders

Ejemplares similares